Medication overuse and chronic migraine: a critical review according to clinical pharmacology

Bibliography

• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808
   PubMed Web of Science ®Google Scholar
• Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep 2011;15:64–9
   PubMed Web of Science ®Google Scholar
• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599–609
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52:1456–70
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008;71:1821–8
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Duru G, Mudge M, et al. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 2011;31:837–50
   PubMed Web of Science ®Google Scholar
• Kim SY, Park SP. The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. J Headache Pain 2014;15:68–75
   PubMedGoogle Scholar
• Westergaard ML, Glümer C, Hansen EH, et al. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014;155:2005–13
   PubMed Web of Science ®Google Scholar
• Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 2010;9:391–401
   PubMed Web of Science ®Google Scholar
• Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009;72(Suppl 5):S3–7
   PubMed Web of Science ®Google Scholar
• Rapoport AM. Analgesic rebound headache. Headache 1988;28:662–5
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache 1990;30:634–8
   PubMed Web of Science ®Google Scholar
• Graff-Radford SB, Bittar GT. The use of methylergonovine (Methergine®) in the initial control of drug induced refractory headache. Headache 1993;33:390–3
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Liberman J, et al. Prevalence of frequent headache in a population sample. Headache 1998;38:497–506
   PubMed Web of Science ®Google Scholar
• Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache 2008;48:16–25
   PubMed Web of Science ®Google Scholar
• Radat F, Creac’h C, Swedsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005;25:519–22
   PubMed Web of Science ®Google Scholar
• Andrasik F, Buse DC, Grazzi L. Behavioral medicine for migraine and medication overuse headache. Curr Pain Headache Rep 2009;13:241–8
   PubMed Web of Science ®Google Scholar
• Diener HC, Katsarava Z, Limmroth V. Headache attributed to a substance or its withdrawal. Handb Clin Neurol 2010;97:589–99
   PubMedGoogle Scholar
• Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 2015;84(7):688–95
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259–87
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(Suppl 2):S31–70
   PubMed Web of Science ®Google Scholar
• Sommerville BK. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975;25:239–44
   PubMed Web of Science ®Google Scholar
• Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother 2014;15:2063–70
   PubMed Web of Science ®Google Scholar
• Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache 2008;48:1186–93
   PubMed Web of Science ®Google Scholar
• Tepper SJ. The role of prevention. Handb Clin Neurol 2010;97:195–205
   PubMedGoogle Scholar
• Silberstein SD. Preventive treatment of migraine. Rev Neurol Dis 2005;2:167–75
   PubMedGoogle Scholar
• Ferrari A, Ottani A, Bertolini A, et al. Adverse reactions related to drugs for headache treatment: clinical impact. Eur J Clin Pharmacol 2005;60:893–900
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia 2010;30:1283
   PubMed Web of Science ®Google Scholar
• Cho SJ, Chu MK. Risk factors of chronic daily headache or chronic migraine. Curr Pain Headache Rep 2015;19:465–73
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicenter, multinational study (COMOESTAS project). Cephalalgia 2014;34:426–33
   PubMed Web of Science ®Google Scholar
• Louter M, Fernandez-Morales J, de Vries B, et al. Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia 2014;1:1–8
   Google Scholar
• Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87–99
   PubMedGoogle Scholar
• Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006;46(Suppl 4):202–11
   Google Scholar
• Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59:1011–14
   PubMed Web of Science ®Google Scholar
• Caproni S, Elisa B, Cupini LM, et al. Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. J Headache Pain 2014;15:88–97
   PubMedGoogle Scholar
• Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 2013;27:867–77
   PubMed Web of Science ®Google Scholar
• Fuh JL, Wang SJ. Dependent behavior in patients with medication-overuse headache. Curr Pain Headache Rep 2012;16:73–9
   PubMed Web of Science ®Google Scholar
• Taghaddosinejad F, Mehrpour O, Afshari R, et al. Factors related to seizure in tramadol poisoning and its blood concentration. J Med Toxicol 2011;7:183–8
   PubMedGoogle Scholar
• Loder E, Weizenbaum E, Frishberg B, et al. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache 2013;53:1651–9
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 2009;13:301–7
   PubMed Web of Science ®Google Scholar
• Saper JR, Lake AE3rd, Bain PA, et al. A practice guide for continuous opioid therapy for refractory daily headache: patients selection, physician requirements, and treatment monitoring. Headache 2010;50:1175–93
   PubMed Web of Science ®Google Scholar
• Eriksen J, Sjøgren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172–9
   PubMed Web of Science ®Google Scholar
• Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache 2009;49:395–403
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:885–94
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 2001;41:953–67
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28:877–86
   PubMed Web of Science ®Google Scholar
• Addicott MA, Yang LL, Peiffer AM, et al. The effect of daily caffeine use on cerebral blood flow: How much caffeine can we tolerate? Hum Brain Mapp 2009;30:3102–14
   PubMed Web of Science ®Google Scholar
• Shapiro RE. Caffeine and headaches. Curr Pain Headache Rep 2008;12:311–15
   PubMed Web of Science ®Google Scholar
• Sullivan JT, Preston KL, Testa MP, et al. Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992;52:635–42
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694–8
   PubMed Web of Science ®Google Scholar
• Lake AE3rd, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache 2009;49:555–62
   PubMed Web of Science ®Google Scholar
• Starling AJ, Hoffman-Snyder C, Halker RB, et al. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist 2011;17:297–9
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157–68
   PubMed Web of Science ®Google Scholar
• Ferrari A, Pasciullo G, Savino G, et al. Headache treatment before and after the consultation of a specialized center: a pharmacoepidemiology study. Cephalalgia 2004;24:356–62
   PubMed Web of Science ®Google Scholar
• Nitter WH, Johnsen LF, Eriksen M. Acute effects of indomethacin on cerebral blood flow in man. Pharmacology 1995;51:48–55
   PubMed Web of Science ®Google Scholar
• Calic Z, Choong H, Schlaphoff G, et al. Reversible cerebral vasoconstriction syndrome following indomethacin. Cephalalgia 2014;34:1181–6
   PubMed Web of Science ®Google Scholar
• Gaytán M, Morales C, Bellido C, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology. Histol Histopathol 2006;21:541–56
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache center--clinical characteristics and treatment outcomes. Cephalalgia 2004;24:483–90
   PubMed Web of Science ®Google Scholar
• Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: an updated review. Arch Toxicol 2015;89:193–9
   PubMed Web of Science ®Google Scholar
• Meng ID, Dodick D, Ossipov MH, et al. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia 2011;31:851–60
   PubMed Web of Science ®Google Scholar
• Cheung V, Amoozegar F, Dilli E. Medication overuse headache. Curr Neurol Neurosci Rep 2015;15:509–16
   PubMedGoogle Scholar
• Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003;43:179–90
   PubMed Web of Science ®Google Scholar
• De Felice M, Ossipov MH, Porreca F. Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 2011;24:193–6
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hutchinson MR, Williams DB, et al. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 2013;33:52–64
   PubMed Web of Science ®Google Scholar
• Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia 2010;30:1101–9
   PubMed Web of Science ®Google Scholar
• Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006;129:543–50
   PubMed Web of Science ®Google Scholar
• Munksgaard SB, Bendtsen L, Jensen RH. Modulation of central sensitization by detoxification in MOH: results of a 12-month detoxification study. Cephalalgia 2013;33:444–53
   PubMed Web of Science ®Google Scholar
• Saper JR, Hamel RL, Lake AE3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005;25:545–6
   PubMed Web of Science ®Google Scholar
• Giannini G, Zanigni S, Grimaldi D, et al. Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study. J Headache Pain 2013;14:49–54
   PubMed Web of Science ®Google Scholar
• Lauwerier E, Paemeleire K, Van Damme S, et al. Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. Pain 2011;152:1334–9
   PubMed Web of Science ®Google Scholar
• Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? Headache 2010;50:1597–611
   PubMed Web of Science ®Google Scholar
• Saper JR, Lake AE3rd. Medication overuse headache: type I and type II. Cephalalgia 2006;26:1262
   PubMed Web of Science ®Google Scholar
• Rossi P, Faroni JV, Tassorelli C, et al. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain 2013;14:10–17
   PubMed Web of Science ®Google Scholar
• Loder E, Biondi D. Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 2003;43:904–9
   PubMed Web of Science ®Google Scholar
• Mauskop A. Simplified butalbital withdrawal protocol. Headache 2004;44:290–1
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell MF, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Library 2014;3:1–85
   Google Scholar
• Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23:19–34
   PubMed Web of Science ®Google Scholar
• Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987;27:130–3
   PubMed Web of Science ®Google Scholar
• Tepper SJ. Chronic migraine and medication overuse headache. Headache 2014;54:1249–50
   PubMed Web of Science ®Google Scholar
• Bøe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 2009;16:705–12
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005;25:12–15
   PubMed Web of Science ®Google Scholar
• Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache center. Cephalalgia 2005;25:1159–67
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache 2013;53(Suppl 2):54–61
   PubMedGoogle Scholar
• Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013;12:244–52
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S. Evidence accumulates on the association between topiramate use early in pregnancy and the risk of oral clefts. Pharmacoepidemiol Drug Saf 2014;23:1026–8
   PubMed Web of Science ®Google Scholar
• Evans RW. A rational approach to the management of chronic migraine. Headache 2013;5:168–76
   Google Scholar
• Robbins L. Refractory chronic migraine: long-term follow-up using a refractory rating scale. J Headache Pain 2012;13:225–9
   PubMed Web of Science ®Google Scholar
• Schulman E. Refractory migraine - a review. Headache 2013;53:599–613
   PubMed Web of Science ®Google Scholar
• Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain 2014;15:47–52
   PubMed Web of Science ®Google Scholar
• Paemeleire K, Louis P, Magis D, et al. Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. Acta Neurol Belg 2015;115(1):1–17
   PubMed Web of Science ®Google Scholar
• Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 2015;11:175–7
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014;13:885–92
   PubMed Web of Science ®Google Scholar
• Tobin JA, Flitman SS. Occipital nerve blocks: effect of symptomatic medication: overuse and headache type on failure rate. Headache 2009;49:1479–85
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Reed KL, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2014;1:1–15
   Google Scholar
• Jürgens TP, Leone M. Pearls and pitfalls: neurostimulation in headache. Cephalalgia 2013;33:512–25
   PubMed Web of Science ®Google Scholar
• Linde M, Stovner LJ, Zwart JA, et al. Time trends in the prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). Cephalalgia 2011;31:585–96
   PubMed Web of Science ®Google Scholar
• Hagen K, Jensen R, Bøe MG, et al. Medication overuse headache: A critical review of end points in recent follow-up studies. J Headache Pain 2010;11:373–7
   PubMed Web of Science ®Google Scholar
• Purdy RA. Closing remarks: what future prospects can we expect in migraine management? Neurol Sci 2013;34(Suppl 1):S23–6
   PubMed Web of Science ®Google Scholar
• Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache--part I: Review of headache treatment compliance. Headache 2006;46:1387–94
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015;35(6):478–88
   PubMed Web of Science ®Google Scholar
• Cowan RP. CAM in the real world: you may practice evidence-based medicine, but your patients don’t. Headache 2014;54:1097–102
   PubMed Web of Science ®Google Scholar
• Ferrari A, Cicero AF, Bertolini A, et al. Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia 2006;26:187–93
   PubMed Web of Science ®Google Scholar
• Hsiang KW, Chen TS, Lin HY, et al. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clin Ther 2010;32:1294–303
   PubMed Web of Science ®Google Scholar
• Gagliardi L. Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr 1985;107:991–2
   PubMed Web of Science ®Google Scholar
• Koomanan N, Ko Y, Yong WP, et al. Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center. Clin Ther 2012;34:2259–67
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Mueller EA, Gerbeau C, et al. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 1997;37:336–43
   PubMed Web of Science ®Google Scholar
• Jørgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991;31:108–10
   PubMed Web of Science ®Google Scholar
• Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391–401
   PubMed Web of Science ®Google Scholar
• De Winter S, Meersseman W, Verelst S, et al. Drug-related admissions due to interaction with an old drug, lithium. Acta Clin Belg 2013;68:356–8
   PubMed Web of Science ®Google Scholar
• Kaufman J, Hamburger R, Matheson J, et al. Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition. J Clin Pharmacol 1981;21:663–7
   PubMed Web of Science ®Google Scholar
• Stewart CF, Fleming RA, Germain BF, et al. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991;34:1514–20
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536–42
   PubMed Web of Science ®Google Scholar
• Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 2014;174:947–53
   PubMed Web of Science ®Google Scholar
• Wang YP, Chen YT, Tsai CF, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014;171:54–61
   PubMed Web of Science ®Google Scholar
• Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med 2013;14:633–8
   PubMed Web of Science ®Google Scholar
• Orr JM, Abbott FS, Farrell K, et al. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982;31:642–9
   PubMed Web of Science ®Google Scholar
• Frazee LA, Reed MD. Warfarin and nonsteroidal anti-inflammatory drugs: why not? Ann Pharmacother 1995;29:1289–91
   PubMed Web of Science ®Google Scholar
• Cowan RA, Hartnell GG, Lowdell CP, et al. Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. Br Med J 1984;289:347–8
   PubMed Web of Science ®Google Scholar
• Liu Y, Ramírez J, Ratain MJ. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 2011;71:917–20
   PubMed Web of Science ®Google Scholar
• Kamali F. The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur J Clin Pharmacol 1993;45:551–3
   PubMed Web of Science ®Google Scholar
• Hynninen VV, Olkkola KT, Leino K, et al. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol 2007;21:651–6
   PubMed Web of Science ®Google Scholar
• Wang J, Hughes TP, Kok CH, et al. Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. Br J Cancer 2012;106:1772–8
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43:144–66
   PubMed Web of Science ®Google Scholar
• Evans RW, Tepper SJ, Shapiro RE, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache 2010;50:1089–99
   PubMed Web of Science ®Google Scholar
• Evans DC, O’Connor D, Lake BG, et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003;31:861–9
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003;43:423–7
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001;52:69–76
   PubMed Web of Science ®Google Scholar
• Van Haarst AD, Van Gerven JM, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999;48:190–6
   PubMed Web of Science ®Google Scholar
• Dixon R, French S, Kemp J, et al. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Investig 1998;15:515–22
   PubMed Web of Science ®Google Scholar
• Venter CP, Joubert PH, Buys AC. Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids. Br Med J 1984;289:288–9
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112–20
   PubMed Web of Science ®Google Scholar
• Blanche P, Rigolet A, Gombert B, et al. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Postgrad Med J 1999;75:546–7
   PubMed Web of Science ®Google Scholar
• Hempel E, Klinger W. Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 1976;12:442–8
   PubMed Web of Science ®Google Scholar
• Garey KW, Amsden GW, Johns CA. Possible interaction between imipramine and butalbital. Pharmacotherapy 1997;17:1041–2
   PubMed Web of Science ®Google Scholar
• Parker AC, Preston T, Heaf D, et al. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994;38:573–6
   PubMed Web of Science ®Google Scholar
• Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin Pharmacol Ther 1990;48:410–18
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Arendt-Nielsen L, Brøsen K, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992;42:587–91
   PubMed Web of Science ®Google Scholar
• Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312–23
   PubMed Web of Science ®Google Scholar
• Boyd IW. Tramadol and seizures. Med J Aust 2005;182:595–6
   PubMed Web of Science ®Google Scholar
• Ghose K. Assessment of peripheral adrenergic activity and its interactions with drugs in man. Eur J Clin Pharmacol 1980;17:233–8
   PubMed Web of Science ®Google Scholar
• Leucht S, Hackl HJ, Steimer W, et al. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl) 2000;147:378–83
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760–811
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review Article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11–19
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705–13
   PubMed Web of Science ®Google Scholar
• Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981;68:50–4
   PubMed Web of Science ®Google Scholar
• Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Exp Opin Drug Metabol Toxicol 2014;10:1457–89
   PubMed Web of Science ®Google Scholar
• Park MK, Lim KS, Kim TE, et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther Drug Monit 2012;34:599–603
   PubMed Web of Science ®Google Scholar
• Hooper WD, Franklin ME, Glue P, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Epilepsia 1996;37:91–7
   PubMed Web of Science ®Google Scholar
• Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511–13
   PubMed Web of Science ®Google Scholar
• Anderson GD, Gidal BE, Kantor ED, et al. Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 1994;35:221–5
   PubMed Web of Science ®Google Scholar
• Redington K, Wells C, Petito F. Erythromycin and valproate interaction. Ann Intern Med 1992;116:877–8
   PubMed Web of Science ®Google Scholar
• Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993;23:307–15
   PubMed Web of Science ®Google Scholar
• Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996;60:48–53
   PubMed Web of Science ®Google Scholar